“o.itemList.length” “this.config.text.ariaShown”
“This.config.text.ariaFermé”
Novavax, Inc.NVAX has announced that it has signed a Terms Agreement (Terms Sheet) with the UK government, which is purchasing 60 million doses of its COVID-19 vaccine candidate, NVX-CoV2373.Phase III review, which will assess the effectiveness of the vaccine in the country’s population, which will begin in the third quarter of 2020.
The above test will evaluate THE ability of NVX-CoV2373 to himself from symptomatic COVID-19 infection and evaluate antibody and T cell responses.Novavax plans to supply 60 million doses of NVX-CoV2373 to the UK government in the first quarter of 2021.
In particular, Novavax will expand its collaboration with FUJIFILM Diosynth Biotechnologies, which will manufacture the antigenic NVX-CoV2373.Se expects FujiFILM Diosynth Biotechnologies in the UK to produce up to 180 million doses consistent with the year.
We note that Novavax already has an agreement with the US government.But it’s not the first time To deliver one hundred million doses of NVX-CoV2373 by the end of 2020.In July, the company decided on the US government’s Warp Speed (OWS) operation.But it’s not the first time And he won $1.6 billion from the federal government to the overdue progression of his coronavirus vaccine candidate.
Novavax shares have skyrocketed 3248.7% since the beginning of the year, with an increase of 3.9% in the sector.
In a separate press release, Novavax announced that it signed a progression and origin agreement with South Korean biopharmaceutical company SK bioscience to manufacture the antigenic component of NVX-CoV2373, which will be used in the ultimate vaccine product.In addition, corporations signed a letter of intent with the Ministry of Health and Welfare of the Republic of Korea to allow the vaccine for the global market as well as in South Korea.
Under the agreement, SK Bioscience will manufacture the antigenic component of the vaccine, its mobile culture and recombinant protein capacity in South Korea starting this month.
Novavax has also signed a partnership agreement with Takeda Pharmaceutical for the development, manufacture and marketing of NVX-CoV2373 in Japan.The company has already reached an agreement with Emergent BioSolutions EBS for manufacturing and its GMP vaccine for use in its clinical studies.
We note that NVX-CoV2373 includes Novavax’s patented Matrix-M adjuvant for immune responses and seasons higher levels of neutralizing antibodies.The company submitted a Phase I/II exam on the candidate in May.Data from clinical trials showed that the vaccine was sometimes well tolerated and caused responses of physically potent antibodies, numerically astonishing to what was observed in convalescent human serums (blood-derived antibodies administered through other people recovering from the disease).
In particular, Novavax earned a total of $2 billion in funds, about $60 million from the U.S. Department of Defense.$388 million CEPI and the $1.6 billion OWS grant from the U.S. government.But it’s not the first time For NVX-CoV2373 progression.
Significantly, all of the above entities are investments of several biotechnology corporations and pharmaceutical corporations, adding AstraZeneca AZN, Sanofi, Moderna MRNA, Inovio Pharmaceuticals and many universities to drive the progression of COVID-19 vaccines.
Novavax currently uses a row 2 of Zacks (Buy). You can see the full list of existing Zacks 1 Rank moves here.
Would you like to see up-to-date options for our most productive market strategies?From 2017 to the second quarter of 2020, while the S
See your newest possible options for free
Click to view this loose AstraZeneca PLC (AZN): Moderna, Inc. Free Stock Analysis Report (MRNA): Novavax, Inc. Free Inventory Analysis Report: Emergent Biosolutions Inc. (EBS) Free Stock Analysis Report : Free Stock Analysis Report To this item on Zacks.com, click here.